42.38 USD
+0.85 (+2.05%)
42.38 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 85% to TERN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 54.63. This target is 28.9% above the current price.
TERN was analyzed by 17 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about TERN.
In the previous month the buy percentage consensus was at a similar level.
TERN was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-11 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-12-09 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-09 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-12-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-12-09 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-09 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-26 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-11-25 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-19 | Truist Securities | Maintains | Buy -> Buy |
| 2025-11-18 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-11-13 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-11-11 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-04 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-11-04 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-04 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-11-04 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-11-03 | William Blair | Upgrade | Market Perform -> Outperform |
| 2025-10-23 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-10-22 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-15 | Truist Securities | Initiate | Buy |
| 2025-09-17 | Barclays | Initiate | Overweight |
| 2025-05-13 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-04-21 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-28 | William Blair | Initiate | Market Perform |
| 2024-12-04 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-12-04 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-12-04 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-11-13 | HC Wainwright & Co. | Maintains | Neutral -> Neutral |
| 2024-10-31 | Oppenheimer | Initiate | Outperform |
TERNS PHARMACEUTICALS INC / TERN FAQ
What do analysts expect the price target to be for TERNS PHARMACEUTICALS INC (TERN)?
17 analysts have analysed TERN and the average price target is 54.63 USD. This implies a price increase of 28.9% is expected in the next year compared to the current price of 42.38.
Can you provide the consensus rating for TERNS PHARMACEUTICALS INC stock?
The consensus rating for TERNS PHARMACEUTICALS INC (TERN) is 84.7059 / 100 . This indicates that analysts generally have a positive outlook on the stock.